Companies sponsors |
Roche Products (glofitamab) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
African Caribbean Leukaemia Trust |
|
Anthony Nolan |
|
Black Health Agency for Equality |
|
Blood Cancer UK |
|
Cancer Black Care |
|
Cancer Equality |
|
Cancer52 |
|
DKMS |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Kevin Karawa Leukaemia Trust |
|
Leukaemia Cancer Society |
|
Leukaemia Care |
|
Leukaemia UK |
|
Lymphoma Action |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
|
WMUK |
Professional groups |
Association of Cancer Physicians |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Oncology Pharmacy Association |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
British Society of Interventional Radiology |
|
British Transplantation Society |
|
Cancer Research UK |
|
NHS Blood and Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society and College of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Cutaneous Lymphoma Group |
|
UK Oncology Nursing Society |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
AbbVie (epcoritamab) |
|
Accord Healthcare (bendamustine, etoposide, gemcitabine, prednisolone, oxaliplatin) |
|
Actavis (bendamustine, etoposide, gemcitabine, prednisolone) |
|
Advanz Pharma (prednisolone) |
|
Aspen (chlorambucil) |
|
Baxter Healthcare (cyclophosphamide, ifosfamide) |
|
Bristol-Myers Squibb Pharmaceuticals (etoposide) |
|
Consilient Health (dexamethasone) |
|
Dr Reddy’s Laboratories UK (bendamustine) |
|
Eli Lilly and Company (gemcitabine) |
|
Hospira UK (gemcitabine, oxaliplatin) |
|
Kite, a Gilead company (axicabtagene ciloleucel) |
|
Medac UK (bendamustine, etoposide, lomustine, oxaliplatin) |
|
Napp Pharmaceuticals (bendamustine, rituximab) |
|
Pfizer (gemcitabine, vincristine) |
|
Ranbaxy (UK), a Sun Pharmaceutical Company (gemcitabine) |
|
Roche (glofitamab, polatuzumab vedotin, rituximab) |
|
Sandoz (cyclophosphamide, rituximab) |
|
Seacross pharmaceuticals (bendamustine) |
|
Swedish Orphan Biovitrum (loncastuximab tesirine) |
|
Teva Nederland B.V. (bleomycin) |
|
Zentiva (bendamustine, prednisolone) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health – Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Cochrane Haematology Group |
|
Cochrane UK |
|
Genomics England |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
Leukaemia UK |
|
Lymphoma Research Trust |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |